BioSpace News Archive

Calyxt, Inc. today announced that a presentation given by management at the H.C Wainwright 23rd Annual Global Investment Conference will be available for viewing online on September 13th at 7:00 a.m. ET . The conference will be held in a virtual meeting format.

Titan Medical Inc. today announced that David McNally, President and CEO of Titan Medical, will present an overview of the company and its Enos™ robotic single access surgical system at the H.C. Wainwright 23rd Annual Global Investment Conference on Monday, September 13, 2021.

Merus N.V., a clinical-stage oncology company developing innovative, full-length multispecific antibodies, announced that Bill Lundberg, M.D., Chief Executive Officer of Merus, will participate in the following investor conferences.

Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, announced that it has entered into a strategic collaboration and license agreement with Genentech, a member of the Roche Group to develop and commercialize allogeneic cell therapies to treat multiple oncology indications.

Evelo Biosciences, Inc., a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced the appointment of Iain McInnes, M.B.Ch.B, Ph.D., to its Board of Directors.

Helius Medical Technologies, Inc., a neurotech company focused on neurological wellness, announced that management will participate in the H.C. Wainwright Annual Global LifeSciences Conference, which is being held virtually from September 13th-15th.

Checkmate Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, announced that Barry Labinger, CEO, will present at the H.C. Wainwright 23rd Annual Global Investment Conference.

Passage Bio, Inc., a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, reported that Maxine Gowen, Ph.D., has been appointed chairwoman of the board of directors for the company, effective August 31.

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic debilitating diseases, announced that Chief Executive Officer Michael Parini is scheduled to present at the following virtual investor conferences:

FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, announced management is scheduled to present at the Baird 2021 Global Healthcare Conference on Tuesday, September 14 at 5:30 PM E.T.